id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-354373-lldfoptb	Chi, Jeffrey	COVID-19 Clinical Research	2020-05-05		.txt	text/plain	2491	153	49	They can be categorized into four groups: drugs that combat SARS-CoV-2, immunomodulatory agents to counteract cytokine storm, convalescence plasma therapies and vaccines trials. They can be categorized into 1) drugs that combat SARS-CoV-2, 2) immunomodulatory agents to counteract cytokine storm, 3) convalescent plasma therapies and 4) vaccines trials (Table 1) . In vitro studies of these agents showed antiviral activities against SARS-VoV-2 and they are now repurposed for treating COVID-19 in clinical trials (Table 1) . Currently there are many ongoing clinical trials (e.g. NCT04292899, NCT04292730) to evaluate the efficacy of remdesivir in patients with mild to moderate or severe COVID-19. Sarilumab, another IL-6 receptor antagonist approved for RA, is also being studied in clinical trials (e.g. NCT04288713) in hospitalized patients with severe COVID-19 (Table 1) . As of April 19, 2020, there were 5 registered convalescent plasma therapy clinical trials in the United States for the treatment of severe and critically ill COVID-19 patients (Table 1) .	./cache/cord-354373-lldfoptb.txt	./txt/cord-354373-lldfoptb.txt